Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Profhilo Structura is an injectable medical device developed using NAHYCO™ Hybrid Technology, designed for the restoration of facial adipose tissue and the treatment of age-related volume loss. It consists of stabilized hybrid cooperative complexes (HCC) of high molecular weight (HMW) and low molecular weight (LMW) hyaluronic acid (HA) at a high concentration (90 mg per 2 mL). Unlike traditional dermal fillers that rely on chemical cross-linking agents like BDDE, Profhilo Structura uses a thermal stabilization process to create a product with high HA concentration and low viscosity. It is specifically indicated for injection into the superficial fat compartments, such as the lateral cheek, where it promotes adipose tissue homeostasis and provides a lifting effect while maintaining a natural appearance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Profhilo Structura.